1 completed, 1 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Recruiting 1 |
Follow Bypassing Agents: new trials by email Literature Review of Bypassing Agents trials Research Report on Bypassing Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates - Von Willebrand Disease, Type 3 | Phase 3 | Recruiting | Hoffmann-La Roche | 75 | 2025-06-27 | 2026-11-16 |
| A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors fitusiran, Bypassing agents - Hemophilia A, Hemophilia B | Phase 3 | Completed | Genzyme, a Sanofi Company | 60 | 2018-02-14 | 2022-03-28 |
Blood Coagulation Disorders (1) · Blood Coagulation Disorders, Inherited (1) · Coagulation Protein Disorders (1) · Genetic Diseases, Inborn (1) · Genetic Diseases, X-Linked (1) · Hematologic Diseases (1) · Hemophilia A (1) · Hemophilia B (1) · Hemorrhagic Disorders (1) · von Willebrand Disease, Type 3 (1)
Genzyme, a Sanofi Company (1) · Hoffmann-La Roche (1)
Canada (2) · France (2) · Germany (2) · Italy (2) · Japan (2) · South Africa (2) · Spain (2) · United Kingdom (2) · United States (2) · Australia (1) · Belgium (1) · China (1) · Colombia (1) · India (1) · Malaysia (1)
PMID 34922648, PMID 35114155, PMID 37003287
2016 (1)